Plus Therapeutics is running a dose optimization trial for REYOBIQ™ in alignment with FDA's Project Optimus.
1 report, 0 independent
Updated Jul 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Plus Therapeutics is running a dose optimization trial for REYOBIQ™ in alignment with FDA's Project Optimus.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Plus Therapeutics
biopharmaceutical company
Nothing else this week.
- FDA
Related events
- SynAct Pharma AB is seeking discussion with the FDA regarding the design of its Phase 3 clinical trials.
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
- EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.
- FDA agreed to reduced sample size for a clinical trial involving X4 Pharmaceuticals.
- NRx Pharmaceuticals and TMS are undergoing various reviews with the FDA, including guidance on real-world evidence and a ketamine ANDA review.
Coverage
Newest first; wire copies grouped- Unknown outlet